<DOC>
	<DOCNO>NCT00722579</DOCNO>
	<brief_summary>The PRESILLION Study non-randomized , multi-center , single-arm study evaluate safety approve Cobalt Chromium bare metal stent system treatment ischemic heart disease attributable stenotic de novo lesion native coronary artery . The study population include 100 patient two de novo native coronary artery lesion maximum lesion length 30mm maximum two major coronary artery reference vessel diameter &gt; = 2.5mm &lt; = 4.0mm visual estimation . Patients follow 1 month 6 month post-procedure assessment MACE adverse event .</brief_summary>
	<brief_title>A Study Presillion Stent de Novo Coronary Lesions</brief_title>
	<detailed_description>The PRESILLION Stent System intend use patient symptomatic ischemic heart disease attributable stenotic de novo lesion native coronary artery reference vessel diameter 2.5 mm 4.0 mm lesion length 30 mm amenable percutaneous treatment coronary stenting . The stent intend permanent implant device . The primary objective study evaluate safety PRESILLION Stent System treatment de novo stenotic lesion native coronary artery . The primary safety measure composite MACE one ( 1 ) month follow . The MACE rate shall meet performance goal bare metal stent order show safety device . The protocol amend data collect time point close possible ( ) 6 month post index procedure non-interventional retrospective manner . The data point contain exactly follow-up information collect 1 month follow-up .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<criteria>The patient must &gt; = 18 year age . Patient eligible percutaneous coronary intervention ( PCI ) . Acceptable candidate coronary artery bypass surgery ( CABG ) . Female patient childbearing potential must negative pregnancy test within 7 day prior enrolment utilize reliable birth control trial duration . Diagnosis angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) unstable angina pectoris ( Braunwald Classification B &amp; C , IIIIII ) patient document silent ischemia . Treatment two de novo native coronary artery lesion maximum two major coronary artery . Target reference vessel diameter lesion must &gt; = 2.5mm &lt; = 4.0mm diameter ( visual estimate ) . Target lesion length must &lt; = 30mm cover one study stent . Target lesion stenosis lesion &gt; 50 % &lt; 100 % ( visual estimate ) . At least TIMI I coronary flow . Patient willing comply specify followup evaluation . Patient must provide write informed consent prior procedure use form approve local Ethics Committee . Recent myocardial infarction ( either STEMI non STEMI &lt; 48 hour prior plan index procedure ) . The patient unstable angina classify Braunwald A IIIIII . The patient unprotected leave main coronary artery disease ( stenosis &gt; 50 % ) . A significant ( &gt; 50 % ) stenosis proximal distal target lesion . Angiographic evidence thrombus within target lesion . Heavily calcify lesion and/or calcify lesion , successfully predilated and/or excessively tortuous vessel make unsuitable stent delivery deployment . Left ventricular ejection fraction &lt; = 25 % . Totally occluded lesion ( TIMI 0 level ) . The patient impair renal function ( creatinine 3.0mg/dL ) time treatment . The patient Cerebrovascular Accident ( CVA ) within past 6 month . Prior stent within 10mm target lesion . The target lesion ostial location ( within 3.0mm vessel origin ) . The target lesion involve bifurcation diseased ( &gt; 50 % stenotic ) branch vessel &gt; = 2.0mm diameter ( side branch require intervention protection ) . The target lesion locate bypass graft . Note : stenting lesion bypass native coronary artery allow . Known allergy follow : aspirin , clopidogrel bisulfate ( Plavix ® ) ticlopidine ( Ticlid ® ) , heparin , cobalt chromium , contrast agent ( manage medically ) . The patient significant medical condition investigator 's opinion may interfere patient 's optimal participation study . The patient currently participate investigational drug device study complete primary endpoint clinically interfere study endpoint . Intervention another lesion within 30 day prior , plan highly probably perform 30 day index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Coronary Artery Disease</keyword>
</DOC>